Edgewise Therapeutics, Inc. (EWTX) Stock Analysis

Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business

Mon, July 13, 2026 at 12:30 PM UTC 4 min read

Servier has successfully completed its acquisition of Edgewise Therapeutics' Muscular Dystrophy Business, a strategic move aimed at enhancing its portfolio in rare disease therapies. This acquisition is significant for investors as it positions Servier to leverage Edgewise's innovative treatments and expand its market presence in the muscular dystrophy sector, potentially driving future revenue growth. Investors should monitor how this integration impacts Servier's overall performance and market strategy moving forward.

Read full article →

Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data

Thu, June 25, 2026 at 12:41 PM UTC 4 min read

Edgewise Therapeutics, Inc. (EWTX) saw its price target raised to $59 following promising data from its heart condition trial. This positive development indicates strong potential for the company's lead product candidate, which could enhance its market position and attract investor interest. As the company progresses in its clinical trials, this news may signal increased confidence in EWTX's growth prospects and future revenue potential.

Read full article →